All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
While partnering activities reached new highs in 2020, Chinese biopharma players found it more difficult to snatch good deals in a more competitive landscape. They now need to act faster and do more preparation work to seize partnering opportunities, panelists said at the Chinabio Partnering Forum.
Venture capitalists in China are adopting different models to quickly create value from biopharma companies and are able to exit much faster than their U.S counterparts, new data suggest.
Multinational players are changing the way they look at China as a source for innovation as it accelerates efforts in areas such as digital health in pursuit of desire to make a global impact.